Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Baxter
Express Scripts
Boehringer Ingelheim
Merck
Dow

Last Updated: September 26, 2022

Claims for Patent: 7,041,786


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Summary for Patent: 7,041,786
Title:Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis
Abstract: A method of treatment of inflamed, pre-cancerous or cancerous tissue or polyps in a mammalian subject is disclosed. The treatment involves administration of a composition of at least one peptide agonist of a guanylate cyclase receptor and/or other small molecules that enhance intracellular production of cGMP. The at least one peptide agonist of a guanylate cyclase receptor may be administered either alone or in combination with an inhibitor of cGMP-dependent phosphodiesterase. The inhibitor may be a small molecule, peptide, protein or other compound that inhibits the degradation of cGMP. Without requiring a particular mechanism of action, this treatment may restore a healthy balance between proliferation and apoptosis in the subject's population of epithelial cells, and also suppress carcinogenesis. Thus, the method may be used to treat, inter alia, inflammation, including gastrointestinal inflammatory disorders, general organ inflammation and asthma, and carcinogenesis of the lung, gastrointestinal tract, bladder, testis, prostate and pancreas, or polyps.
Inventor(s): Shailubhai; Kunwar (Blue Bell, PA), Nikiforovich; Gregory (St. Louis, MO), Jacob; Gary S. (Creve Coeur, MO)
Assignee: Callisto Pharmaceuticals (New York, NY)
Application Number:10/107,814
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,041,786
Patent Claims: 1. A peptide consisting of the amino acid sequence of SEQ ID NO:20.

2. A composition in unit dose comprising a guanylate cyclase receptor agonist peptide consisting of the amino acid sequence of SEQ ID NO:20.

3. A composition in unit dose form comprising: a) a guanylate cyclase receptor agonist peptide consisting of the amino acid sequence of SEQ ID NO: 20; and b) at least one compound selected from the group consisting of: a cGMP-dependent phosphodiesterase inhibitor, an anti-inflammatory agent, an antiviral agent and an anticancer agent.

4. The composition of either claim 2 or 3, wherein the unit dose form is selected from the group consisting of a tablet, a capsule, a solution and an inhalation formulation.

5. The composition of either claim 2 or 3, further comprising one or more excipients.

6. A peptide conjugate comprising polyethylene glycol (PEG) attached to a peptide consisting of the amino acid sequence SEQ ID NO:20.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKesson
Harvard Business School
Dow
Colorcon
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.